Suppr超能文献

病毒性肝炎最新进展:成就与展望。

Viral hepatitis update: Progress and perspectives.

机构信息

Virology Institute, CONICET, School of Medical Sciences, National University of Córdoba, Cordoba X5016, Argentina.

Multidisciplinary Institute for Investigation in Pediatric Pathologies (IMIPP) CONICET-GCBA, Laboratory of Molecular Biology, Pathology Division, Ricardo Gutiérrez Children's Hospital, CABA C1425, Buenos Aires, Argentina.

出版信息

World J Gastroenterol. 2021 Jul 14;27(26):4018-4044. doi: 10.3748/wjg.v27.i26.4018.

Abstract

Viral hepatitis, secondary to infection with hepatitis A, B, C, D, and E viruses, are a major public health problem and an important cause of morbidity and mortality. Despite the huge medical advances achieved in recent years, there are still points of conflict concerning the pathogenesis, immune response, development of new and more effective vaccines, therapies, and treatment. This review focuses on the most important research topics that deal with issues that are currently being solved, those that remain to be solved, and future research directions. For hepatitis A virus we will address epidemiology, molecular surveillance, new susceptible populations as well as environmental and food detections. In the case of hepatitis B virus, we will discuss host factors related to disease, diagnosis, therapy, and vaccine improvement. On hepatitis C virus, we will focus on pathogenesis, immune response, direct action antivirals treatment in the context of solid organ transplantation, issues related to hepatocellular carcinoma development, direct action antivirals resistance due to selection of resistance-associated variants, and vaccination. Regarding hepatitis D virus, we describe diagnostic methodology, pathogenesis, and therapy. Finally, for hepatitis E virus, we will address epidemiology (including new emerging species), diagnosis, clinical aspects, treatment, the development of a vaccine, and environmental surveillance.

摘要

病毒性肝炎,继发于甲型、乙型、丙型、丁型和戊型肝炎病毒感染,是一个主要的公共卫生问题,也是发病率和死亡率的重要原因。尽管近年来在医学上取得了巨大的进步,但在发病机制、免疫反应、新型和更有效的疫苗、疗法和治疗的发展方面仍存在一些争议。本综述重点介绍了与当前正在解决的问题、有待解决的问题以及未来研究方向有关的最重要的研究课题。对于甲型肝炎病毒,我们将讨论流行病学、分子监测、新的易感人群以及环境和食品检测。对于乙型肝炎病毒,我们将讨论与疾病、诊断、治疗和疫苗改进有关的宿主因素。对于丙型肝炎病毒,我们将重点关注发病机制、免疫反应、在实体器官移植背景下直接作用抗病毒治疗、与肝细胞癌发展相关的问题、由于耐药相关变异体的选择而导致的直接作用抗病毒药物耐药性以及疫苗接种。关于丁型肝炎病毒,我们将描述诊断方法学、发病机制和治疗。最后,对于戊型肝炎病毒,我们将讨论流行病学(包括新出现的物种)、诊断、临床方面、治疗、疫苗的开发和环境监测。

相似文献

1
Viral hepatitis update: Progress and perspectives.
World J Gastroenterol. 2021 Jul 14;27(26):4018-4044. doi: 10.3748/wjg.v27.i26.4018.
2
Present and future management of viral hepatitis.
World J Gastroenterol. 2021 Dec 21;27(47):8081-8102. doi: 10.3748/wjg.v27.i47.8081.
3
Clinical diagnosis of viral hepatitis: Current status and future strategies.
Diagn Microbiol Infect Dis. 2024 Mar;108(3):116151. doi: 10.1016/j.diagmicrobio.2023.116151. Epub 2023 Nov 30.
4
Viral hepatitis: impressive advances but still a long way to eradication of the disease.
Liver Int. 2014 Feb;34 Suppl 1:1-3. doi: 10.1111/liv.12422.
5
HEP DART 2003: Frontiers in drug development for viral hepatitis.
Expert Opin Investig Drugs. 2004 Mar;13(3):289-93. doi: 10.1517/13543784.13.3.289.
6
[Progress in diagnosis and treatment of viral hepatitis in children].
Zhonghua Gan Zang Bing Za Zhi. 2021 Jan 20;29(1):16-20. doi: 10.3760/cma.j.cn501113-20201229-00684.
7
Progress and challenges in the comprehensive management of chronic viral hepatitis: Key ways to achieve the elimination.
World J Gastroenterol. 2021 Jul 14;27(26):4004-4017. doi: 10.3748/wjg.v27.i26.4004.
8
Pathogenesis, diagnosis and management of hepatitis C.
J Hepatol. 2000;32(1 Suppl):98-112. doi: 10.1016/s0168-8278(00)80419-5.
9
Viral hepatitis in solid organ transplantation other than liver.
J Hepatol. 2011 Aug;55(2):474-82. doi: 10.1016/j.jhep.2011.01.003. Epub 2011 Jan 15.
10
Bridging basic science and clinical research: the EASL Monothematic Conference on Translational Research in Viral Hepatitis.
J Hepatol. 2014 Sep;61(3):696-705. doi: 10.1016/j.jhep.2014.05.016. Epub 2014 May 15.

引用本文的文献

2
An in-depth investigation of NAs-induced osteoporosis adverse events: a real-world, network toxicology and molecular docking analysis.
Front Med (Lausanne). 2025 Jul 4;12:1605024. doi: 10.3389/fmed.2025.1605024. eCollection 2025.
3
4
Liver disorders and phytotherapy.
Toxicol Rep. 2025 May 10;14:102047. doi: 10.1016/j.toxrep.2025.102047. eCollection 2025 Jun.
5
Recent Advances in mRNA-Based Vaccines Against Several Hepatitis Viruses.
Biol Proced Online. 2025 Jun 3;27(1):20. doi: 10.1186/s12575-025-00269-2.
6
Anti-HBs persistence and anamnestic response among medical interns vaccinated in infancy.
Sci Rep. 2025 May 9;15(1):16213. doi: 10.1038/s41598-025-00055-w.
7
Epidemiology of Hepatitis D Virus and Associated Factors in Patients Referred to Level Three Hepatitis Clinic, Fars Province, Southern Iran.
Iran J Med Sci. 2025 Apr 1;50(4):220-228. doi: 10.30476/ijms.2024.101949.3469. eCollection 2025 Apr.
10
CRIPSR-Cas for hepatitis virus: a systematic review and meta-analysis of diagnostic test accuracy studies.
Front Microbiol. 2025 Mar 3;16:1509890. doi: 10.3389/fmicb.2025.1509890. eCollection 2025.

本文引用的文献

1
Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC.
J Hepatocell Carcinoma. 2020 Dec 1;7:347-360. doi: 10.2147/JHC.S279657. eCollection 2020.
2
Treatment of hepatitis C virus infection.
Clin Res Hepatol Gastroenterol. 2021 Jul;45(4):101578. doi: 10.1016/j.clinre.2020.11.008. Epub 2020 Dec 4.
3
Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end.
World J Gastroenterol. 2020 Nov 21;26(43):6770-6781. doi: 10.3748/wjg.v26.i43.6770.
4
Foodborne transmission of hepatitis A and hepatitis E viruses: A literature review.
Int J Food Microbiol. 2021 Jan 2;338:108986. doi: 10.1016/j.ijfoodmicro.2020.108986. Epub 2020 Nov 19.
5
Direct-Acting Antivirals and Organ Transplantation: Is There Anything We Can't Do?
J Infect Dis. 2020 Nov 27;222(Suppl 9):S794-S801. doi: 10.1093/infdis/jiaa420.
6
Interplay between Hepatitis D Virus and the Interferon Response.
Viruses. 2020 Nov 20;12(11):1334. doi: 10.3390/v12111334.
7
Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy.
J Hepatol. 2021 Apr;74(4):801-810. doi: 10.1016/j.jhep.2020.11.017. Epub 2020 Nov 19.
8
Immune system control of hepatitis C virus infection.
Curr Opin Virol. 2021 Feb;46:36-44. doi: 10.1016/j.coviro.2020.10.002. Epub 2020 Nov 1.
9
Reversal of Immunity After Clearance of Chronic HCV Infection-All Reset?
Front Immunol. 2020 Oct 8;11:571166. doi: 10.3389/fimmu.2020.571166. eCollection 2020.
10
Hepatitis A and Hepatitis E: Clinical and Epidemiological Features, Diagnosis, Treatment, and Prevention.
Clin Microbiol Newsl. 2020 Nov 1;42(21):171-179. doi: 10.1016/j.clinmicnews.2020.10.001. Epub 2020 Oct 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验